Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group

Title: Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group
Authors: Herbaux, Charles; Bachy, Emmanuel; Bouabdallah, Reda; Guidez, Stéphanie; Casasnovas, Olivier; Feugier, Pierre; Damaj, Gandhi; Tilly, Hervé; Ysebaert, Loïc; Le Gouill, Steven; Morineau, Nadine; Gyan, Emmanuel; Gressin, Rémy; Houot, Roch; Cheminant, Morgane; Morschhauser, Franck; Thieblemont, Catherine; Haioun, Corinne; Nicolas‐Virelizier, Emmanuelle; Fornecker, Luc‐Matthieu; Daguindau, Nicolas; Cartron, Guillaume
Contributors: Roche
Source: British Journal of Haematology ; volume 207, issue 1, page 110-122 ; ISSN 0007-1048 1365-2141
Publisher Information: Wiley
Publication Year: 2025
Collection: Wiley Online Library (Open Access Articles via Crossref)
Description: Summary Developing new therapeutic regimens for relapsed/refractory (R/R) B non‐Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti‐CD20‐containing immunochemotherapy regimen. We report here the final analysis of the phase II LYSA‐promoted multicentre trial (NCT03276468) of this combination in follicular lymphoma (FL, n = 58), diffuse large B‐cell lymphoma (DLBCL, n = 58) and marginal zone lymphoma (MZL, n = 20). The primary end‐point for FL and DLBCL was not met: ATE, OBI, and VEN resulted in an overall response rate (ORR) at the end of induction (EOI) of 53.6% for FL (cohort 1) and 23.6% for DLBCL (cohort 2) when a minimum of 70% and 48% was expected respectively. The median progression‐free survival was 11.0 and 2.7 months in cohorts 1 and 2 respectively. In cohort 3 (MZL), the ORR at the EOI was evaluated at 66.7%. The most frequent adverse events (AEs) were cytopenias. We also observed 7.4% of autoimmune AE imputable to the combination. In this phase II study, ATE, OBI and VEN demonstrated moderate efficacy and a manageable toxicity profile when used as induction and maintenance therapy.
Document Type: article in journal/newspaper
Language: English
DOI: 10.1111/bjh.20109
Availability: https://doi.org/10.1111/bjh.20109; https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.20109
Rights: http://creativecommons.org/licenses/by-nc-nd/4.0/
Accession Number: edsbas.84F70FE0
Database: BASE